Group 1 - The core viewpoint of the article highlights that Rongchang Biologics (09995) has seen a stock price increase of over 5%, currently trading at 90 HKD with a transaction volume of 1.52 billion HKD, following the acceptance of its RC288 injection application by NMPA [1] - RC288, a PSMA/B7H3ADC developed by Rongchang Biologics, has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - According to Guotai Junan Securities, Rongchang Biologics is expected to enter a new growth phase starting in 2026, primarily benefiting from the launch of new indications for RC18, RC48, and RC28, which will be included in medical insurance [1] Group 2 - The overseas indications for RC48 and RC18 are projected to be launched and sold starting in 2027, contributing to sales revenue for the company [1] - From 2025, the company is anticipated to achieve multiple asset licensing agreements, with upfront payments and milestones expected to be confirmed in the coming years, enhancing the financial statements [1] - The newly entered global FIC pipeline, including CDCP1ADC RC278 and B7H3/PSMA ADC RC288, possesses potential global competitiveness and may lead to licensing opportunities [1]

Core Viewpoint - Rongchang Biopharma (09995) has seen its stock price increase by over 5%, currently trading at 90 HKD, following the acceptance of its RC288 injection application by NMPA, indicating strong market interest in its innovative drug pipeline [1] Group 1: Product Development - The RC288 injection, developed by Rongchang Biopharma, is a PSMA/B7H3 ADC that has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - The company is expected to enter a new growth phase starting in 2026, primarily driven by the launch of new indications for RC18, RC48, and RC28, which will also be included in medical insurance [1] Group 2: Future Revenue Streams - Sales from overseas indications for RC48 and RC18 are projected to begin in 2027, contributing to revenue through sales sharing agreements [1] - Starting in 2025, the company anticipates multiple asset licensing agreements, with upfront payments and milestones expected to enhance financial statements in the coming years [1] Group 3: Competitive Positioning - The newly entered global FIC pipeline, including CDCP1 ADC RC278 and B7H3/PSMA ADC RC288, holds potential global competitiveness and may lead to external licensing opportunities [1]

Coal Mining Research - The report discusses the historical impact of geopolitical conflicts on coal prices, suggesting that these conflicts may stabilize seasonal price declines and elevate average prices. The ongoing geopolitical tensions, particularly involving the US, Israel, and Iran, have led to higher oil and natural gas prices, which are expected to influence energy prices upward. International coal prices have risen by 20% in response to the surge in natural gas prices, leading to increased expectations for coal demand amid high energy prices [3][4] - Domestic coal supply remains stable, but a reduction in imports due to rising international coal prices may elevate domestic seasonal coal price bottoms, making significant price drops unlikely. The peak supply-demand pressure is expected to end around March-April, with a seasonal increase in electricity coal demand starting in May [3][4] Construction Engineering Research - China Power Construction Corporation (中国电建) is highlighted for its leadership in global clean energy construction, with a significant market share in wind, solar, and hydropower projects. The company has completed over 80% of river planning and more than 65% of large and medium-sized hydropower station construction in China, and it leads over 50% of the global market for large and medium-sized hydropower projects [6][7] - The report notes that the integration of computing and electricity has been included in government reports, which is expected to benefit companies involved in integrated computing and electricity operations. The company has signed contracts worth 210.06 billion yuan for digital transformation projects, including data centers and computing centers [5][7] Biopharmaceutical Research - Rongchang Biopharmaceutical (荣昌生物) is projected to enter a new growth phase starting in 2026, driven by the launch of new indications for its products RC18, RC48, and RC28, which are expected to enter medical insurance coverage. The company anticipates revenue of 32.51 billion yuan in 2025, increasing to 78.32 billion yuan in 2026, and 62.79 billion yuan in 2027 [8][31] - The report emphasizes the potential of RC148, a dual antibody product, which is expected to gain market share through partnerships and new indications, enhancing the company's competitive position in the global oncology market [9][32]

Investment Rating - The report assigns an "Accumulate" rating to Rongchang Biopharma with a target price of 143.89 RMB [4]. Core Insights - The report predicts that Rongchang Biopharma will enter a new growth phase starting in 2026, driven by the launch of new indications for RC18, RC48, and RC28, which are expected to enter the medical insurance coverage [11][15]. - The company is expected to achieve revenue of 32.51 billion RMB in 2025, 78.32 billion RMB in 2026, and 62.79 billion RMB in 2027, with a significant increase in net profit anticipated in 2026 [3][11]. Financial Summary - Total revenue is projected to grow from 1,083 million RMB in 2023 to 7,832 million RMB in 2026, reflecting a growth rate of 140.9% [3]. - Net profit (attributable to the parent company) is expected to turn positive in 2025 with a forecast of 644 million RMB, and further increase to 5,031 million RMB in 2026 [3]. - Earnings per share (EPS) is projected to rise from -2.68 RMB in 2023 to 8.91 RMB in 2026 [3]. Revenue Growth Drivers - The anticipated growth is attributed to the approval and market entry of new indications for RC48 and RC18, as well as the expected launch of RC28 [15][21]. - RC48 is set to be approved for first-line treatment of UC and HER2 low-expressing breast cancer, which will significantly expand its market potential [16][21]. - RC18 is expected to see increased volume as it enters medical insurance coverage for multiple indications, including MG and IgAN [21][25]. Strategic Partnerships - The company has entered into several strategic partnerships, including the licensing of RC148 to AbbVie, which is expected to enhance its global competitive position in oncology [34][36]. - The partnership with Santen Pharmaceutical for RC28 is also expected to maximize its market potential in the ophthalmic sector [30]. Clinical Development Pipeline - The report highlights the ongoing clinical trials for RC148, which show promising efficacy in treating various cancers, including NSCLC [36][38]. - RC18 is advancing in global clinical trials, with significant potential for treating MG and other autoimmune diseases [25][26]. Market Positioning - Rongchang Biopharma is positioned to leverage its innovative drug pipeline and strategic partnerships to capture significant market share in the oncology and autoimmune sectors [11][34].

2026 年展望：加入全球肿瘤一线竞争 荣昌生物(688331) | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 廖博闻(研究助理) | 021-23187268 | liaobowen@gtht.com | S0880125042239 | 本报告导读： 本篇报告是我们对荣昌生物 2025 年的回顾梳理，以及 2026 年的展望 | [Table_Invest] | 首次覆盖 | | --- | --- | | 评级 | 增持 | | 目标价格 | 143.89 | [当前价格： Table_CurPrice] 118.90 [Table_Market] 交易数据 | 52 周内股价区间(元) | 29.80-118.90 | | --- | --- | | 总市值( ...

Investment Rating - The report assigns an "Outperform" rating for the industry, indicating a relative performance better than the benchmark index [2][4]. Core Insights - The pharmaceutical sector experienced a mild rebound, with the SW Pharmaceutical Biotechnology Index increasing by 0.50%, ranking 25th out of 31 in the primary industry indices. Notably, the medical consumables and other biological products sectors performed well, while CXO and chemical preparations lagged [2]. - Chinese innovation in ADC (Antibody-Drug Conjugates) was highlighted at the ASCO GU 2026 conference, showcasing promising clinical data for DB-1311 in metastatic castration-resistant prostate cancer, with a median radiographic progression-free survival (rPFS) of 11.3 months and a median overall survival (mOS) of 22.5 months [2]. - The success of the second-phase clinical trial for UBT251, a long-acting GLP-1/GIP/GCG tri-target agonist, was reported, showing an average weight loss of 19.7% in participants after 24 weeks of treatment. The company plans to initiate phase three clinical trials soon [2]. Summary by Sections Industry Performance - The A-share pharmaceutical sector's performance was subdued, with a 1.08% increase in the Shanghai and Shenzhen 300 Index during the week following the Spring Festival. The medical consumables sector saw a notable increase of 3.99% [2]. Clinical Developments - At the ASCO GU 2026 conference, over 70 research outcomes from Chinese experts were presented, with significant updates from several companies on ADC therapies, indicating a strong potential for ADC combined with immunotherapy in first-line cancer treatments [2]. - The report emphasizes the importance of ADCs, dual antibodies, small nucleic acids, and weight-loss drugs as key investment opportunities in the pharmaceutical sector [2]. Investment Recommendations - The report suggests that despite recent market fluctuations and a downturn in Hong Kong's innovative drug sector, the long-term trend of innovation in China's pharmaceutical industry remains positive. It highlights the potential for investment in ADCs, dual antibodies, and other high-growth areas [2].

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry, but it suggests a positive outlook based on upcoming catalysts and potential drug approvals. Core Insights - The biopharmaceutical sector is expected to see significant developments in 2026, with multiple domestic drugs anticipated to report key clinical data. This includes drugs from companies like Betta Pharmaceuticals, Hutchison China MediTech, and CanSino Biologics, which are expected to read out critical clinical data in 2026 [3][21]. - The report emphasizes that the long-term theme for the innovative drug sector is international expansion, with several sub-themes to focus on, including overseas business development (BD) licensing, key clinical trials, and unexpected overseas sales growth [3][18]. Summary by Sections Weekly New Drug Market Review - From December 22 to December 28, 2025, the top five gainers in the new drug sector were Dongyao Pharmaceutical (+23.15%), Beihai Kangcheng (+19.27%), Junshengtai (+16.41%), Shiyao Group (+6.95%), and Ailis (+5.78%). The top five losers were Gakos (-16.11%), Jiahe Biotech (-10.29%), Laika Pharmaceuticals (-9.33%), Yunding Xinyao (-8.98%), and Yongtai Biotech (-6.94%) [1][14]. Weekly Focused Stocks - The report suggests focusing on several stocks with high overseas expansion potential, including: 1. Companies with MNC certification and high overseas volume certainty: Sanofi, United Pharmaceuticals, and Kelun-Biotech. 2. Companies with overseas data catalysts: Betta Pharmaceuticals, Hutchison China MediTech, and InnoCare Pharma. 3. Potential heavyweights for overseas MNC licensing: Junshi Biosciences, Shiyao Group, and Yifang Biotech. 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18]. Weekly New Drug Approval & Acceptance Status - This week, 23 new drug or new indication applications were approved in China, and 10 new drug or new indication applications were accepted [4][19]. Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 99 new drug clinical applications were approved, and 64 new drug clinical applications were accepted [5][24]. Key Domestic Market Events - Notable events include: 1. Xiansheng Zhaoming announced a global exclusive licensing agreement with Ipsen for an ADC drug, potentially worth up to $1.06 billion. 2. He Yu Pharmaceuticals received approval for its CSF-1R selective small molecule inhibitor. 3. Tongyi Pharmaceuticals announced a licensing agreement for a peptide conjugate drug for prostate cancer, with potential payments totaling around $2 billion [10]. Key Overseas Market Events - Significant overseas events include: 1. Novo Nordisk received FDA approval for a 25mg oral semaglutide tablet for weight loss. 2. Sanofi announced a cash acquisition agreement for Dynavax Technologies Corporation, valued at approximately $2.2 billion. 3. Agios Pharmaceuticals announced FDA approval for an oral PK activator for treating α or β thalassemia in adult patients [11].

Investment Rating - The industry investment rating is "Overweight" [6] Core Insights - Yum China reported Q3 2025 revenue of $3.2 billion, a year-on-year increase of 4%, and core operating profit of $399 million, up 8%, aligning with expectations [1][4] - The net new store openings for KFC and Pizza Hut reached a record high in Q3, with a total of 536 new stores, bringing the total to 17,514 [2][4] - Same-store sales for KFC increased by 2% year-on-year, while Pizza Hut saw a 1% increase, marking the 12th consecutive quarter of positive same-store sales growth [5] Summary by Sections Overseas Catering - Yum China achieved Q3 2025 revenue of $3.2 billion, a 4% increase year-on-year, and core operating profit of $399 million, an 8% increase, meeting expectations [1][4] - KFC and Pizza Hut net new store openings reached a record high in Q3, with 536 new stores added, totaling 17,514 stores [2][4] - KFC's same-store sales increased by 2% year-on-year, with transaction volume up 3% and average ticket price down 1% to 38 yuan [5] Overseas Pharmaceuticals - Rongchang Biologics reported a 42.3% year-on-year revenue increase in the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [8] - In Q3, revenue grew by 33.1% year-on-year and 8.7% quarter-on-quarter, reaching 622 million yuan, with a net loss of 101 million yuan, narrowing by 65.2% year-on-year [8] - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan in the first three quarters [8] Overseas Education - The education sector's growth rate has bottomed out, with New Oriental's revenue growth accelerating due to its strong reputation [3] - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [15] - New Oriental's GMV on Douyin was approximately 170 million yuan for the week, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [16]

Investment Rating - The report maintains an "Overweight" rating for the overseas consumer services sector, indicating a positive outlook for the industry [1]. Core Insights - Yum China reported a revenue of $3.2 billion for Q3 2025, a year-on-year increase of 4%, with core operating profit rising by 8% to $399 million, aligning with expectations [1][4]. - The company achieved a record net store opening of 536 locations in Q3, bringing the total to 17,514 stores, with KFC and Pizza Hut expanding into over 310 and 170 new cities respectively [2][4]. - Same-store sales for KFC grew by 2% year-on-year, driven by a 3% increase in transaction volume, while Pizza Hut's same-store sales increased by 1% with a significant 17% rise in transaction volume [5]. Summary by Sections Overseas Consumer Services - Yum China accelerated its store opening pace in Q3 2025, achieving a total of 536 new stores, with KFC at 12,640 and Pizza Hut at 4,022 [2][4]. - The company has entered over 310 new cities for KFC and 170 for Pizza Hut in the past 12 months, with a total of approximately 2,500 and 1,000 cities served respectively [2][4]. - New store formats, such as KFC Coffee and KPRO, are expanding consumer engagement and market presence [2][4]. Overseas Pharmaceuticals - Rongchang Bio reported a 42.3% year-on-year revenue growth for the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [9]. - The third quarter saw a revenue increase of 33.1% year-on-year, amounting to 622 million yuan, with a net loss of 101 million yuan, a significant reduction of 65.2% year-on-year [9]. - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan, while sales expenses increased by 32.1% to 823 million yuan, with a sales expense ratio decline of 3.7 percentage points to 47.8% [9]. Overseas Education - The education sector's growth has stabilized, with New Oriental experiencing a revenue acceleration driven by its strong brand reputation [16]. - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [16]. - New Oriental's GMV on Douyin was approximately 170 million yuan, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [17].

Core Insights - The report highlights a significant divergence in performance across various sectors within the public REITs market for Q3 2025, with utility, rental housing, and consumer sectors showing robust growth, while logistics and transportation sectors are underperforming [4][14] - The overall market experienced a V-shaped rebound in October, driven by the central bank's resumption of public bond trading, leading to a notable increase in trading volume and a recovery in valuations [5][14] Sector Performance Summary - **Utility Sector**: Demonstrated exceptional performance with EBITDA growth exceeding 10% year-on-year, indicating strong demand and operational efficiency [4][14] - **Rental Housing and Consumer Sectors**: Both sectors showed steady performance with positive year-on-year growth in revenue, EBITDA, and distributable amounts, reflecting resilience in consumer spending [4][14] - **Logistics and Transportation Sectors**: These sectors faced significant challenges, with over 80% of companies in the industrial park sector reporting declines in performance, and only a few companies in the transportation sector achieving growth [4][14] - **Energy Sector**: Overall performance declined, with most projects reporting significant year-on-year decreases in revenue and EBITDA, except for a few standout companies [4][14] Market Trends - **Dividend Yields**: The latest dividend yield for property REITs rose to 4.06%, with a spread of 2.27% over the 10-year government bond yield, indicating a favorable investment environment for income-seeking investors [5][14] - **Valuation Recovery**: Valuations for property and operating rights REITs have rebounded to the 66% and 72% percentiles, respectively, suggesting a recovery in investor confidence [5][14] - **New REITs Performance**: A significant disparity in the performance of newly established REITs was noted, with only 14% of those established in 2025 meeting their expected distributable amounts [4][14] Company-Specific Insights - **Ding Tai Gao Ke (301377)**: Reported a revenue of 1.457 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 29.13%, with a notable profit increase of 63.94% [13] - **Rongchang Bio (09995.HK)**: Achieved a revenue of 1.72 billion yuan in the first three quarters of 2025, a 42.3% increase year-on-year, with a significant reduction in net losses [15][16] - **Zhong Tung Gao Xin (000657)**: Announced plans for capacity expansion in response to high demand for PCB drill bits, with a projected increase in monthly production capacity [20][21]